Topic

is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment.

Articles

Instead, incorporate ESG into your long-term business planning.

Why You Don’t Need a Dedicated ESG Strategy

Role drift and clinical trials among many areas for compliance professionals to keep an eye on in 2022.

Insights from Informa’s Pharmaceutical Compliance Congress 

Cross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.


A Better Way to Combat Patent Trolls

William Borden is a freelance journalist covering the pharmaceutical industry. He is based in New Jersey.

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip 

Partner in Crowell & Moring's Life Sciences Litigation, Intellectual Property, and Trade Secrets groups in New York

New technology serves as reminder for the appropriate uses of CRISPR.

CRISPR: Maximizing this Revolutionary Genetic Tool While Minimizing IP Risk

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

As the pressure on teams reviewing promotional content has increases, both in terms of volumes of content and complexity, Sameer Lal discusses the need for a near-term strategies using artificial intelligence (AI) and machine learning (ML) to decongest bottlenecks of the manual review process.

Optimizing the Review Process for Promotional Content

 is Managing Director of Iperion - a Deloitte business, where he leads a team of regulatory/IDMP experts active in various projects to deliver value to both pharmaceutical companies as well as regulators. In addition to having more than two decades’ industry and consultancy experience, Frits is regarded internationally as a subject matter expert on IDMP and he proactively shares his rich knowledge and experience wherever he can. Iperion, now part of Deloitte, is a globally-operating life sciences consultancy firm which is paving the way to digital healthcare, by supporting standardization and ensuring the right technology, systems and processes are in place to enable insightful business decision-making and innovation.

The Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.

Why Pharma’s Approach to IDMP Today Will Matter to Patients & Physicians Tomorrow

Partner in Wiggin and Dana’s Corporate and Litigation Departments and a member of the Life Sciences Practice Group

Assistant General Counsel of Emergent Biosolutions

Understanding of recent legal developments can help companies avoid infringement. 

Recent Federal Circuit Developments in Patent Licensing

Emily Lowe, Michele Buenafe, and Kelli Boyle — Morgan, Lewis & Bockius LLP.

The eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.

Digital-Deal Alignment: Considerations for Tech Agreements

In an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.

Legal